2024-520317-49-00撤回1 期
Intraperitoneal treatment with fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor in patients with multi-quadrant peritonitis undergoing abdominal surgery: A randomized placebo-controlled trial (TRIPLE)
Region Sjaelland, Reponex Pharmaceuticals A/S2 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2025年6月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- Primary translational endpoint: Change in cytokine levels in peritoneal dialysate.
研究概览
简要总结
To investigate if intraperitoneal administration of GM-CSF, metronidazole and fosfomycin can optimize the treatment of patients with multiquadrant peritonitis
研究设计
- 分配方式
- Randomized
- 主要目的
- Triple
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •All patients age ≥ 18 undergoing surgical intervention with findings of peritonitis, due to a lesion in the large intestine, with the involvement of ≥2 quadrants
排除标准
- •Patients with a previous allergic reaction to rhGM-CSF, fosfomycin or metronidazole - Patients with American Society of Anesthesiologists (ASA) physical status >3 - Patients with WHO Performance status >3 - Patients with peritoneal carcinomatosis - Patients currently in treatment for any malignant or hematological disease - Patients active prescribed immunosuppressants - Patients with an autoimmune disease in active treatment with immunomodulatory drugs - Patients with the need of vacuum assisted closure (VAC) - Participating in another pharmacological intervention trial - Patients currently pregnant or breastfeeding. - Patients with severe renal failure (eGFR < 30 ml/min) - Patients with anticipated compliance problems as determined by the investigator
结局指标
主要结局
Primary translational endpoint: Change in cytokine levels in peritoneal dialysate.
Primary translational endpoint: Change in cytokine levels in peritoneal dialysate.
Primary clinical end point: Change in QoR-15
Primary clinical end point: Change in QoR-15
次要结局
- Macrophage phagocytosis assay on PBMCs
- Change in cytokine levels in peripheral blood (TNF-α, IL-1β, IL-6, IL-8, IL-10, MCP-1, GM-CSF)
- Change in various blood values: • Hematology, • K+, • Na+, • CRP, • Albumin, • Creatinine (incl. eGFR)
研究者
Ismail Gögenur
Scientific
Region Sjaelland
研究点 (2)
Loading locations...
相似试验
招募中
1 期
GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA SurgeryPouchitisNCT04979832Zealand University Hospital18
招募中
2 期
A combined treatment with GM-CSF, fosfomycin and metronidazole for pouchitis in ulcerative colitis patients after restorative ileal pouch anal anastomosis surgery. A clinical safety and proof-of-concept studyPouchitis2024-517764-38-00Region Sjaelland, Reponex Pharmaceuticals A/S18
已完成
2 期
Intraperitoneal Administration of Fosfomycin, Metronidazole and Molgramostim Versus Intravenous Antibiotics for Perforated AppendicitisAppendicitis PerforatedNCT03435900Herlev Hospital13
进行中（未招募）
1 期
Antibiotic agents administrated in the abdominal cavity compared with antibiotic agents administrated intravenously for treatment of perforated appendicitisEUCTR2017-004753-16-DKDepartment of Surgery, Herlev Hospital12
Unknown
不适用
Efficacy of Intravenous Fosfomycin in the Treatment of Complicated Urinary in Real-life Conditions.Complicated Urinary Tract InfectionNCT04076436Fundación Pública Andaluza para la gestión de la Investigación en Sevilla400